-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
MMT5-14
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2719679-31-7.gif)
| Category | SARS-CoV |
| CAS | 2719679-31-7 |
| Description | MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). |
Product Information
| Molecular Weight | 766.86 |
| Molecular Formula | C39H55N6O8P |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | MMT5-14 (10 μM; 0-12 h) increases epithelial cell uptake MMT5-14 (5 μM; 2 d) shows a better in vitro antiviral activity than remdesivir Cell Viability Assay Cell Line: Vero-E6 cell line Concentration: 5 Incubation Time: 2 days Result: Inhibited SARS-CoV-2, alpha, beta, gamma and delta variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. |
| In Vivo | MMT5-14 (10 mg/kg; i.v. once) shows a higher stability than remdesivir in microsomes, and shows higher concentrations of prodrugs and active metabolites (NTP) in blood and lungs. |
| Target | SARS-CoV |
